How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,179 results for

Hepatotoxic Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Hepatotoxicity induced by herbal and dietary supplements. (PubMed)

Hepatotoxicity induced by herbal and dietary supplements. Herbals and dietary supplements (HDS) can cause hepatotoxicity. Regulation of HDS varies across the globe. In the United States, it is defined by a law that is now two decades old. More recent regulatory approaches in Europe still do not require testing for premarket safety. The true incidence of hepatotoxicity from HDS is unknown. The presentation is most often with a hepatocellular enzyme pattern, and the outcomes can be severe (...) , leading to transplantation in some circumstances. The diagnosis of hepatotoxicity due to HDS is made in the same way as for drugs. However, patients often must be coaxed into revealing a history of use. No causality assessment approach is perfectly suited for hepatotoxicity from HDS, but the Roussel Uclaf Causality Assessment Method is most used. Future endeavors must focus on defining epidemiology, establishing an accepted nomenclature, and identifying culprit ingredients, predisposing host factors

2014 Seminars in Liver Disease

42. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. (PubMed)

Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand. Buprenorphine/naloxone (BUP/NX), an effective treatment for opioid dependence, has been implicated in hepatic toxicity. However, as persons taking BUP/NX have multiple hepatic risk factors, comparative data are needed to quantify the risk of hepatoxicity with BUP/NX.We compared rates of alanine aminotransferase (ALT (...) ) elevation≥grade 3 (ALT≥5.1 times the upper limit of normal) and graded bilirubin elevations in HIV-negative opioid injectors randomized to long-term (52 weeks) or short-term (18 days) medication assisted treatment (LT-MAT and ST-MAT, respectively) with BUP/NX in a multisite trial conducted in China and Thailand. ALT and bilirubin were measured at baseline, 12, 26, 40 and 52 weeks, times temporally remote from BUP/NX exposure in the ST-MAT participants.Among1036 subjects with at least one laboratory

Full Text available with Trip Pro

2014 Drug and alcohol dependence

43. Drug-induced hepatotoxicity: incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients. (PubMed)

Drug-induced hepatotoxicity: incidence of abnormal liver function tests consistent with volatile anaesthetic hepatitis in trauma patients. Volatile anaesthetic drug-induced liver injury can range from asymptomatic alanine transaminase elevations to fatal hepatic necrosis. There is very limited research regarding hepatotoxicity of modern volatile anaesthetic agents. The aim of this study was to determine how common liver injury consistent with volatile anaesthetic hepatitis is, following (...) exposure to isoflurane, desflurane and sevoflurane; and to propose risk factors for its development.Following ethics approval, we conducted a retrospective audit of adult trauma patients with abnormal liver biochemistry following volatile anaesthesia during January 1 to December 31, 2009. The data collected included patient demographics, volatile anaesthetic administration, concurrent medication, perioperative liver biochemistry results and comorbidities. The Council for International Organisations

2014 Liver International

44. The quest for an evidence-based approach to surveillance for methotrexate-related hepatotoxicity: Promise and perils. (PubMed)

The quest for an evidence-based approach to surveillance for methotrexate-related hepatotoxicity: Promise and perils. 25523838 2015 08 04 2019 03 13 1365-2133 172 6 2015 Jun The British journal of dermatology Br. J. Dermatol. The quest for an evidence-based approach to surveillance for methotrexate-related hepatotoxicity: promise and perils. 1684-1685 10.1111/bjd.13620 Dawwas M F MF Division of Digestive Diseases and Nutrition, Department of Medicine, University of Kentucky Medical Center, 800

2014 The British journal of dermatology

45. Hepatotoxicity Induced by Trimethoprim-Sulfamethoxazole in a Child with Cystic Fibrosis (PubMed)

Hepatotoxicity Induced by Trimethoprim-Sulfamethoxazole in a Child with Cystic Fibrosis Patients with cystic fibrosis (CF) have chronic and progressive lung infections with various bacterial organisms that require treatment with oral and intravenous antibiotics on a regular basis. Trimethoprim-sulfamethoxazole (TMP-SMX) is one of the medications used to treat acute pulmonary infectious exacerbations in patients with CF. Hepatic toxicity secondary to TMP-SMX was previously described in normal

Full Text available with Trip Pro

2014 The Journal of Pediatric Pharmacology and Therapeutics : JPPT

46. Isoniazid Hepatotoxicity: Progress in Understanding the Immunologic Component (PubMed)

Isoniazid Hepatotoxicity: Progress in Understanding the Immunologic Component 24037911 2014 04 28 2018 12 11 1527-3350 59 3 2014 Mar Hepatology (Baltimore, Md.) Hepatology Isoniazid hepatotoxicity: progress in understanding the immunologic component. 746-8 10.1002/hep.26707 James Laura L Department of Pediatrics, University of Arkansas for Medical Sciences, Section of Clinical Pharmacology and Toxicology, Arkansas Children's Hospita, Little Rock, AR. Roberts Dean D eng DK081406 DK NIDDK NIH HHS

Full Text available with Trip Pro

2014 Hepatology (Baltimore, Md.)

47. Hepatotoxicity of molecular targeted therapy (PubMed)

Hepatotoxicity of molecular targeted therapy A constant increase in occurrence of neoplasms is observed; hence new methods of therapy are being intensively researched. One of the methods of antineoplastic treatment is molecular targeted therapy, which aims to influence individual processes occurring in cells. Using this type of medications is associated with unwanted effects resulting from the treatment. Liver damage is a major adverse effect diagnosed during targeted therapy. Drug-induced (...) liver damage can occur as necrosis of hepatocytes, cholestatic liver damage and cirrhosis. Hepatotoxicity is evaluated on the basis of International Consensus Criteria. Susceptibility of the liver to injury is connected not only with toxicity of the used medications but also with metastasis, coexistence of viral infections or other chronic diseases as well as the patient's age. It has been proven that in most cases the liver injury is caused by treatment with multikinase inhibitors, in particular

Full Text available with Trip Pro

2014 Contemporary Oncology

48. Drug-Induced Hepatotoxicity (Diagnosis)

. Excluding other causes of liver injury is essential. A positive dechallenge is a 50% fall in serum transaminase levels within 8 days of stopping the drug. A positive dechallenge is very helpful in cases of use of multiple medications. Previously documented reactions to a drug aid in diagnosis. Deliberate rechallenge in clinical situations is unethical and should not be attempted; however, inadvertent rechallenge in the past has provided valuable evidence that the drug was indeed hepatotoxic (...) with serious underlying medical illness. Fluconazole-associated hepatotoxicity is usually, but not always, reversible upon discontinuation of therapy. Isoniazid Severe and fatal hepatitis has been reported with INH therapy. The risk of developing hepatitis is age related, with an incidence of 8 cases per 1000 persons older than 65 years. In addition, the risk of hepatitis is increased with daily consumption of alcohol. Mild hepatic dysfunction evidenced by a transient elevation of serum transaminase levels

2014 eMedicine.com

49. Halothane Hepatotoxicity (Overview)

necrosis from 1959-1962. [ ] This study found that, of 82 cases of fatal hepatic necrosis, 9 cases were deemed likely to be drug induced. Seven of the 9 patients had received halothane. Based on this study, the risk of fatal halothane hepatotoxicity was estimated to be 1 in 35,000. When the World Health Organization (WHO) drug monitoring database was reviewed for the medications that most commonly cause fatal hepatotoxicity; halothane was one of the 10 most common causes. Given this risk, halothane (...) unexplainable fatal hepatic necrosis after halothane administration in 1 per 35,000 cases. The incidence after administration of other halogenated agents is much lower, including 2 cases per 1 million patients after enflurane administration, a few reports after isoflurane administration, and a single confirmed case after desflurane administration. International Review of the WHO database of medications that cause fatal hepatotoxicity revealed that halothane is one of the top 10 most likely medications

2014 eMedicine.com

50. Isoniazid Hepatotoxicity (Overview)

be continued despite low-grade hepatotoxicity. Patients who are severely affected may have few symptoms until potentially lethal liver damage has occurred. Guidelines for the diagnosis, treatment, control, and prevention of tuberculosis, including the medications used, have been established by the American Thoracic Society (ATS), the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA). [ ] Awareness of INH poisoning may prevent severe morbidity (...) Isoniazid Hepatotoxicity (Overview) Isoniazid Toxicity: Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgwNTU0LW92ZXJ2aWV3 processing > Isoniazid Toxicity Updated: Feb 07

2014 eMedicine.com

51. Drug-Induced Hepatotoxicity (Overview)

. Excluding other causes of liver injury is essential. A positive dechallenge is a 50% fall in serum transaminase levels within 8 days of stopping the drug. A positive dechallenge is very helpful in cases of use of multiple medications. Previously documented reactions to a drug aid in diagnosis. Deliberate rechallenge in clinical situations is unethical and should not be attempted; however, inadvertent rechallenge in the past has provided valuable evidence that the drug was indeed hepatotoxic (...) with serious underlying medical illness. Fluconazole-associated hepatotoxicity is usually, but not always, reversible upon discontinuation of therapy. Isoniazid Severe and fatal hepatitis has been reported with INH therapy. The risk of developing hepatitis is age related, with an incidence of 8 cases per 1000 persons older than 65 years. In addition, the risk of hepatitis is increased with daily consumption of alcohol. Mild hepatic dysfunction evidenced by a transient elevation of serum transaminase levels

2014 eMedicine.com

52. Halothane Hepatotoxicity (Treatment)

Halothane Hepatotoxicity (Treatment) Halothane Hepatotoxicity Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTY2MjMyLXRyZWF0bWVudA== processing (...) > Halothane Hepatotoxicity Treatment & Management Updated: Oct 17, 2016 Author: Ruben Peralta, MD, FACS; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM Share Email Print Feedback Close Sections Sections Halothane Hepatotoxicity Treatment Medical Care No specific therapy is available for either fulminant hepatic necrosis or mild hepatotoxicity due to halothane. Only supportive therapy and orthotopic liver transplantation are available for hepatic necrosis. Because halothane hepatitis

2014 eMedicine.com

53. Isoniazid Hepatotoxicity (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgwNTU0LXRyZWF0bWVudA== processing > Isoniazid Toxicity Treatment & Management Updated: Feb 07, 2019 Author: Joseph L D'Orazio, MD, FAAEM; Chief Editor: BS Anand, MD Share Email Print Feedback Close Sections Sections Isoniazid Toxicity Treatment Approach Considerations Medical care for isoniazid (INH) hepatotoxicity is essentially supportive. Discontinue INH and any other potentially toxic drug, and closely monitor the patient. Hospitalize persons who are more severely affected (eg, with significant elevation (...) undergoing INH prophylaxis may detect early cases of hepatotoxicity. Previous Next: Consultations Consider consultation with a medical toxicologist, if available, for bedside evaluation. US Poison Help Line 1-800-222-1222 (affiliated with the American Academy of Poison Control Centers) is available 24 hours, 7 days a week if a medical toxicologist is not available at your institution. Consider a psychiatric consultation in all cases of intentional overdose before the patient is discharged from

2014 eMedicine.com

54. Drug-Induced Hepatotoxicity (Treatment)

. Excluding other causes of liver injury is essential. A positive dechallenge is a 50% fall in serum transaminase levels within 8 days of stopping the drug. A positive dechallenge is very helpful in cases of use of multiple medications. Previously documented reactions to a drug aid in diagnosis. Deliberate rechallenge in clinical situations is unethical and should not be attempted; however, inadvertent rechallenge in the past has provided valuable evidence that the drug was indeed hepatotoxic (...) with serious underlying medical illness. Fluconazole-associated hepatotoxicity is usually, but not always, reversible upon discontinuation of therapy. Isoniazid Severe and fatal hepatitis has been reported with INH therapy. The risk of developing hepatitis is age related, with an incidence of 8 cases per 1000 persons older than 65 years. In addition, the risk of hepatitis is increased with daily consumption of alcohol. Mild hepatic dysfunction evidenced by a transient elevation of serum transaminase levels

2014 eMedicine.com

55. Isoniazid Hepatotoxicity (Follow-up)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgwNTU0LXRyZWF0bWVudA== processing > Isoniazid Toxicity Treatment & Management Updated: Feb 07, 2019 Author: Joseph L D'Orazio, MD, FAAEM; Chief Editor: BS Anand, MD Share Email Print Feedback Close Sections Sections Isoniazid Toxicity Treatment Approach Considerations Medical care for isoniazid (INH) hepatotoxicity is essentially supportive. Discontinue INH and any other potentially toxic drug, and closely monitor the patient. Hospitalize persons who are more severely affected (eg, with significant elevation (...) undergoing INH prophylaxis may detect early cases of hepatotoxicity. Previous Next: Consultations Consider consultation with a medical toxicologist, if available, for bedside evaluation. US Poison Help Line 1-800-222-1222 (affiliated with the American Academy of Poison Control Centers) is available 24 hours, 7 days a week if a medical toxicologist is not available at your institution. Consider a psychiatric consultation in all cases of intentional overdose before the patient is discharged from

2014 eMedicine.com

56. Drug-Induced Hepatotoxicity (Follow-up)

. Excluding other causes of liver injury is essential. A positive dechallenge is a 50% fall in serum transaminase levels within 8 days of stopping the drug. A positive dechallenge is very helpful in cases of use of multiple medications. Previously documented reactions to a drug aid in diagnosis. Deliberate rechallenge in clinical situations is unethical and should not be attempted; however, inadvertent rechallenge in the past has provided valuable evidence that the drug was indeed hepatotoxic (...) with serious underlying medical illness. Fluconazole-associated hepatotoxicity is usually, but not always, reversible upon discontinuation of therapy. Isoniazid Severe and fatal hepatitis has been reported with INH therapy. The risk of developing hepatitis is age related, with an incidence of 8 cases per 1000 persons older than 65 years. In addition, the risk of hepatitis is increased with daily consumption of alcohol. Mild hepatic dysfunction evidenced by a transient elevation of serum transaminase levels

2014 eMedicine.com

57. Halothane Hepatotoxicity (Follow-up)

Halothane Hepatotoxicity (Follow-up) Halothane Hepatotoxicity Treatment & Management: Medical Care, Surgical Care, Consultations Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTY2MjMyLXRyZWF0bWVudA== processing (...) > Halothane Hepatotoxicity Treatment & Management Updated: Oct 17, 2016 Author: Ruben Peralta, MD, FACS; Chief Editor: Michael R Pinsky, MD, CM, Dr(HC), FCCP, MCCM Share Email Print Feedback Close Sections Sections Halothane Hepatotoxicity Treatment Medical Care No specific therapy is available for either fulminant hepatic necrosis or mild hepatotoxicity due to halothane. Only supportive therapy and orthotopic liver transplantation are available for hepatic necrosis. Because halothane hepatitis

2014 eMedicine.com

58. Halothane Hepatotoxicity (Diagnosis)

necrosis from 1959-1962. [ ] This study found that, of 82 cases of fatal hepatic necrosis, 9 cases were deemed likely to be drug induced. Seven of the 9 patients had received halothane. Based on this study, the risk of fatal halothane hepatotoxicity was estimated to be 1 in 35,000. When the World Health Organization (WHO) drug monitoring database was reviewed for the medications that most commonly cause fatal hepatotoxicity; halothane was one of the 10 most common causes. Given this risk, halothane (...) unexplainable fatal hepatic necrosis after halothane administration in 1 per 35,000 cases. The incidence after administration of other halogenated agents is much lower, including 2 cases per 1 million patients after enflurane administration, a few reports after isoflurane administration, and a single confirmed case after desflurane administration. International Review of the WHO database of medications that cause fatal hepatotoxicity revealed that halothane is one of the top 10 most likely medications

2014 eMedicine.com

59. Isoniazid Hepatotoxicity (Diagnosis)

be continued despite low-grade hepatotoxicity. Patients who are severely affected may have few symptoms until potentially lethal liver damage has occurred. Guidelines for the diagnosis, treatment, control, and prevention of tuberculosis, including the medications used, have been established by the American Thoracic Society (ATS), the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA). [ ] Awareness of INH poisoning may prevent severe morbidity (...) Isoniazid Hepatotoxicity (Diagnosis) Isoniazid Toxicity: Background, Pathophysiology, Etiology Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTgwNTU0LW92ZXJ2aWV3 processing > Isoniazid Toxicity Updated: Feb 07

2014 eMedicine.com

60. A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>